Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study

Abstract Background and Objective Patients with heart failure or cardio/renal dysfunction (chronic kidney disease, end-stage kidney disease, or heart failure) are at increased risk of hyperkalemia. Sodium zirconium cyclosilicate (SZC) treats hyperkalemia, but the impact of SZC treatment duration on...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Abiy Agiro, Fan Mu, Erin E. Cook, Ali Greatsinger, Jingyi Chen, Manasvi Sundar, Angela Zhao, Ellen Colman, Arun Malhotra
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Adis, Springer Healthcare 2025-10-01
Цуврал:	Drugs - Real World Outcomes
Онлайн хандалт:	https://doi.org/10.1007/s40801-025-00525-7
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!